Mutational heterogeneity in cancer and the search for new cancer-associated genes

…, D Voet, M Noble, D DiCara, P Lin, L Lichtenstein… - Nature, 2013 - nature.com
Major international projects are underway that are aimed at creating a comprehensive catalogue
of all the genes responsible for the initiation and progression of cancer 1 , 2 , 3 , 4 , 5 , 6 …

Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine

…, A Kiezun, D Voet, M Lawrence, LT Lichtenstein… - Nature medicine, 2014 - nature.com
Translating whole-exome sequencing (WES) for prospective clinical use may have an impact
on the care of patients with cancer; however, multiple innovations are necessary for clinical …

[PDF][PDF] Integrated genomic characterization of papillary thyroid carcinoma

…, E Lander, MS Lawrence, D Lee, E Lee, S Lee, W Lee… - Cell, 2014 - cell.com
Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer. Here, we
describe the genomic landscape of 496 PTCs. We observed a low frequency of somatic …

[HTML][HTML] Prospective derivation of a living organoid biobank of colorectal cancer patients

…, SL Carter, A McKenna, MS Lawrence, L Lichtenstein… - Cell, 2015 - cell.com
In Rspondin-based 3D cultures, Lgr5 stem cells from multiple organs form ever-expanding
epithelial organoids that retain their tissue identity. We report the establishment of tumor …

Comprehensive molecular profiling of lung adenocarcinoma: The cancer genome atlas research network

…, K Cibulskis, J Kim, C Stewart, L Lichtenstein… - Nature, 2014 - espace.curtin.edu.au
Adenocarcinoma of the lung is the leading cause of cancer death worldwide. Here we
report molecular profiling of 230 resected lung adenocarcinomas using messenger RNA, …

Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma

…, JC Pignon, AD Cherniack, L Lichtenstein… - Nature medicine, 2020 - nature.com
PD-1 blockade has transformed the management of advanced clear cell renal cell carcinoma
(ccRCC), but the drivers and resistors of the PD-1 response remain incompletely elucidated…

Landscape of genomic alterations in cervical carcinomas

AI Ojesina, L Lichtenstein, SS Freeman, CS Pedamallu… - Nature, 2014 - nature.com
Cervical cancer is responsible for 10–15% of cancer-related deaths in women worldwide 1 ,
2 . The aetiological role of infection with high-risk human papilloma viruses (HPVs) in …

Discovery and characterization of artifactual mutations in deep coverage targeted capture sequencing data due to oxidative DNA damage during sample preparation

…, TJ Fennell, C Stewart, L Lichtenstein… - Nucleic acids …, 2013 - academic.oup.com
As researchers begin probing deep coverage sequencing data for increasingly rare
mutations and subclonal events, the fidelity of next generation sequencing (NGS) laboratory …

Oncotator: cancer variant annotation tool

AH Ramos, L Lichtenstein, M Gupta… - Human …, 2015 - Wiley Online Library
Oncotator is a tool for annotating genomic point mutations and short nucleotide insertions/deletions
(indels) with variant‐ and gene‐centric information relevant to cancer researchers. …

Calling somatic SNVs and indels with Mutect2

…, T Sato, K Cibulskis, G Getz, C Stewart, L Lichtenstein - BioRxiv, 2019 - biorxiv.org
Mutect2 is a somatic variant caller that uses local assembly and realignment to detect SNVs
and indels. Assembly implies whole haplotypes and read pairs, rather than single bases, as …